胰高血糖素样肽-1受体——是与否？ - Suppr

The glucagon-like peptide-1 receptor--or not?

作者信息

Pyke Charles, Knudsen Lotte Bjerre

出版信息

Endocrinology. 2013 Jan;154(1):4-8. doi: 10.1210/en.2012-2124.

DOI:10.1210/en.2012-2124

PMID:23267050

Abstract

摘要

相似文献

The glucagon-like peptide-1 receptor--or not?

Endocrinology. 2013 Jan;154(1):4-8. doi: 10.1210/en.2012-2124.

Glucagon-like peptide-1 and diabetes 2012.

Exp Diabetes Res. 2012;2012:768760. doi: 10.1155/2012/768760. Epub 2012 Dec 31.

GLP-1 receptor agonists today.

Diabetes Res Clin Pract. 2011 Sep;93(3):317-27. doi: 10.1016/j.diabres.2011.01.004. Epub 2011 Jul 20.

The development of non-peptide glucagon-like peptide-1 receptor agonist for the treatment of type 2 diabetes.

Arch Pharm Res. 2011 Jul;34(7):1041-3. doi: 10.1007/s12272-011-0721-z.

Medicinal chemistry of glucagon-like peptide receptor agonists.

Prog Med Chem. 2013;52:45-96. doi: 10.1016/B978-0-444-62652-3.00002-8.

[Beyond glycemic control in type 2 diabetes. Promises and gambles of therapy with glucagon-like peptide-1 receptor agonists].

G Ital Cardiol (Rome). 2011 Dec;12(12 Suppl 2):3-4. doi: 10.1714/985.10683.

[Glucagon-like peptide-1 receptor agonists].

Nihon Rinsho. 2012 May;70 Suppl 3:689-92.

Integrating incretin-based therapy into type 2 diabetes management.

J Fam Pract. 2013 Jun;62(6 Suppl CME):S1-8.

Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials.

Curr Opin Clin Nutr Metab Care. 2008 Jul;11(4):491-9. doi: 10.1097/MCO.0b013e328302f414.

Glucagon-like peptide-1 (GLP-1) receptor agonism or DPP-4 inhibition does not accelerate neoplasia in carcinogen treated mice.

Regul Pept. 2012 Nov 10;179(1-3):91-100. doi: 10.1016/j.regpep.2012.08.016. Epub 2012 Sep 15.

引用本文的文献

Lighting up targets of dual agonist therapies for diabetes and obesity.

Nat Metab. 2025 Aug;7(8):1507-1508. doi: 10.1038/s42255-025-01346-2.

Cystic fibrosis-related diabetes is associated with reduced islet protein expression of GLP-1 receptor and perturbation of cell-specific transcriptional programs.

Sci Rep. 2024 Oct 28;14(1):25689. doi: 10.1038/s41598-024-76722-1.

Adipocyte inflammation is the primary driver of hepatic insulin resistance in a human iPSC-based microphysiological system.

Nat Commun. 2024 Sep 12;15(1):7991. doi: 10.1038/s41467-024-52258-w.

Transforming Diabetes Care: The Molecular Pathways through Which GLP1-RAs Impact the Kidneys in Diabetic Kidney Disease.

Biomedicines. 2024 Mar 14;12(3):657. doi: 10.3390/biomedicines12030657.

Drug repositioning in thyroid cancer treatment: the intriguing case of anti-diabetic drugs.

Front Pharmacol. 2023 Dec 11;14:1303844. doi: 10.3389/fphar.2023.1303844. eCollection 2023.

The GLP-1-mediated gut-kidney cross talk in humans: mechanistic insight.

Am J Physiol Cell Physiol. 2024 Feb 1;326(2):C567-C572. doi: 10.1152/ajpcell.00476.2023. Epub 2023 Dec 18.

The locus coeruleus contributes to the anorectic, nausea, and autonomic physiological effects of glucagon-like peptide-1.

Sci Adv. 2023 Sep 22;9(38):eadh0980. doi: 10.1126/sciadv.adh0980. Epub 2023 Sep 20.

Glucagon-like peptide 1 receptor agonists: cardiovascular benefits and mechanisms of action.

Nat Rev Cardiol. 2023 Jul;20(7):463-474. doi: 10.1038/s41569-023-00849-3. Epub 2023 Mar 28.

Revealing the tissue-level complexity of endogenous glucagon-like peptide-1 receptor expression and signaling.

Nat Commun. 2023 Jan 18;14(1):301. doi: 10.1038/s41467-022-35716-1.

Use of GLP-1 Receptor Agonists and Occurrence of Thyroid Disorders: a Meta-Analysis of Randomized Controlled Trials.

Front Endocrinol (Lausanne). 2022 Jul 11;13:927859. doi: 10.3389/fendo.2022.927859. eCollection 2022.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

The glucagon-like peptide-1 receptor--or not?

作者信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

相似文献

引用本文的文献